SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 5, 2000
TANOX, INC.
(Exact name of Registrant as specified in charter)
Delaware 000-30231 76-0196733
(State or other jurisdiction of (Commission (IRS Employer
incorporation) File Number) Identification No.)
1031 Stella Link, Houston, Texas 77025
(Address of principal executive offices) (Zip Code)
Registrant's telephone number including area code: (713) 664-2288
<PAGE>
ITEM 5. OTHER EVENTS.
On June 5, 2000, Registrant, Genentech, Inc. and Novartis Pharmaceuticals
Corporation announced the submission of a Biologics License Application with the
U.S. Food and Drug Administration for anti-IgE (rhuMAb-E25 or E25), a
recombinant humanized monoclonal antibody to immunoglobulin E (IgE), in the
Press Release which is attached hereto as Exhibit 99.1 and incorporated herein
by reference. E25 may represent the first in a new class of therapies that block
IgE. E25 is designed to intervene in the allergic process by binding to
circulating IgE, an antibody that triggers the release of inflammatory
mediators. These mediators are involved in the allergic cascade and cause the
symptoms of allergy. E25 prevents IgE from bindng to mast cells, thereby
blocking the consequent release of these inflammatory mediators.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial Statements of Business Acquired
Not Applicable
(b) Pro Forma Financial Information
Not Applicable
(c) Exhibits
99.1 Press Release Dated June 5, 2000
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned herein to duly authorized.
Dated: June 5, 2000
TANOX, INC.
By: /s/ NANCY T. CHANG
Nancy T. Chang, President
and Chief Executive Officer
